| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
J Clin Oncol
|
2010
|
14.41
|
|
2
|
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
|
J Clin Oncol
|
2006
|
11.26
|
|
3
|
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.
|
J Clin Oncol
|
2005
|
8.56
|
|
4
|
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
|
J Clin Oncol
|
2004
|
6.59
|
|
5
|
Weekly paclitaxel in the adjuvant treatment of breast cancer.
|
N Engl J Med
|
2008
|
6.54
|
|
6
|
Adjuvant chemotherapy in older women with early-stage breast cancer.
|
N Engl J Med
|
2009
|
5.68
|
|
7
|
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
|
J Clin Oncol
|
2014
|
5.61
|
|
8
|
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting.
|
J Clin Oncol
|
2006
|
4.61
|
|
9
|
Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis.
|
JAMA
|
2008
|
4.48
|
|
10
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
|
Arch Pathol Lab Med
|
2010
|
4.38
|
|
11
|
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
|
J Clin Oncol
|
2008
|
4.29
|
|
12
|
Systematic review: gene expression profiling assays in early-stage breast cancer.
|
Ann Intern Med
|
2008
|
3.32
|
|
13
|
Breast cancer. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2009
|
3.17
|
|
14
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
Arch Pathol Lab Med
|
2010
|
2.72
|
|
15
|
Transitioning to breast cancer survivorship: perspectives of patients, cancer specialists, and primary care providers.
|
J Gen Intern Med
|
2009
|
2.70
|
|
16
|
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
|
J Clin Oncol
|
2012
|
2.62
|
|
17
|
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
J Oncol Pract
|
2010
|
2.59
|
|
18
|
Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis.
|
J Clin Oncol
|
2010
|
2.46
|
|
19
|
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
|
J Clin Oncol
|
2012
|
2.45
|
|
20
|
Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study.
|
J Gen Intern Med
|
2009
|
2.36
|
|
21
|
Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002.
|
J Clin Oncol
|
2009
|
2.26
|
|
22
|
HER2 testing in breast cancer: NCCN Task Force report and recommendations.
|
J Natl Compr Canc Netw
|
2006
|
2.15
|
|
23
|
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.
|
Cancer Res
|
2011
|
2.12
|
|
24
|
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood.
|
Clin Cancer Res
|
2012
|
2.07
|
|
25
|
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
|
J Clin Oncol
|
2007
|
2.01
|
|
26
|
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.
|
J Clin Oncol
|
2009
|
1.98
|
|
27
|
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer.
|
J Natl Compr Canc Netw
|
2006
|
1.88
|
|
28
|
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer.
|
J Clin Oncol
|
2012
|
1.85
|
|
29
|
Breast cancer, version 3.2013: featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2013
|
1.79
|
|
30
|
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
|
N Engl J Med
|
2015
|
1.76
|
|
31
|
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.
|
J Natl Compr Canc Netw
|
2009
|
1.73
|
|
32
|
Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.
|
J Clin Oncol
|
2011
|
1.69
|
|
33
|
Breast cancer version 3.2014.
|
J Natl Compr Canc Netw
|
2014
|
1.63
|
|
34
|
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623.
|
J Clin Oncol
|
2007
|
1.59
|
|
35
|
Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer.
|
Cancer
|
2012
|
1.52
|
|
36
|
Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support.
|
J Clin Oncol
|
2006
|
1.48
|
|
37
|
Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
|
J Clin Oncol
|
2010
|
1.44
|
|
38
|
Invasive breast cancer.
|
J Natl Compr Canc Netw
|
2011
|
1.43
|
|
39
|
Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
|
Oncology (Williston Park)
|
2007
|
1.39
|
|
40
|
Impact of gene expression profiling tests on breast cancer outcomes.
|
Evid Rep Technol Assess (Full Rep)
|
2007
|
1.35
|
|
41
|
Quality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls.
|
J Clin Oncol
|
2013
|
1.32
|
|
42
|
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
|
Clin Cancer Res
|
2004
|
1.31
|
|
43
|
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.
|
Oncologist
|
2013
|
1.29
|
|
44
|
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2012
|
1.23
|
|
45
|
Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI.
|
Breast Cancer Res Treat
|
2007
|
1.21
|
|
46
|
Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer.
|
Cancer Res
|
2014
|
1.19
|
|
47
|
Implementing a breast cancer registry and treatment plan/summary program in clinical practice: a pilot program.
|
Cancer
|
2012
|
1.17
|
|
48
|
Colorectal cancer outcomes, recurrence, and complications in persons with and without diabetes mellitus: a systematic review and meta-analysis.
|
Dig Dis Sci
|
2010
|
1.17
|
|
49
|
Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice.
|
Support Care Cancer
|
2007
|
1.14
|
|
50
|
Feasibility and value of PatientViewpoint: a web system for patient-reported outcomes assessment in clinical practice.
|
Psychooncology
|
2012
|
1.14
|
|
51
|
Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
|
J Natl Cancer Inst
|
2012
|
1.13
|
|
52
|
The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
|
J Natl Compr Canc Netw
|
2013
|
1.11
|
|
53
|
Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
|
Breast Cancer Res Treat
|
2011
|
1.10
|
|
54
|
Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis.
|
Diabetes Care
|
2010
|
1.08
|
|
55
|
Clinical Practice Guidelines in Oncology: Translating Evidence Into Practice (and back).
|
J Oncol Pract
|
2005
|
1.07
|
|
56
|
Symptoms, supportive care needs, and function in cancer patients: how are they related?
|
Qual Life Res
|
2008
|
0.99
|
|
57
|
Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer.
|
Acad Radiol
|
2010
|
0.98
|
|
58
|
Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30.
|
Qual Life Res
|
2010
|
0.97
|
|
59
|
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.97
|
|
60
|
The role of informatics in promoting patient-centered care.
|
Cancer J
|
2011
|
0.96
|
|
61
|
Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole.
|
J Clin Pharmacol
|
2011
|
0.95
|
|
62
|
The adjuvant treatment of HER2-positive breast cancer.
|
Curr Treat Options Oncol
|
2012
|
0.95
|
|
63
|
Therapeutic options in the management of metastatic breast cancer.
|
Oncology (Williston Park)
|
2008
|
0.95
|
|
64
|
Quality of end-of-life care for patients with advanced cancer in an academic medical center.
|
J Palliat Med
|
2011
|
0.94
|
|
65
|
Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications.
|
Technol Cancer Res Treat
|
2004
|
0.92
|
|
66
|
Invasive breast cancer.
|
J Natl Compr Canc Netw
|
2007
|
0.92
|
|
67
|
Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole.
|
Cancer Prev Res (Phila)
|
2011
|
0.90
|
|
68
|
Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.
|
Cancer
|
2010
|
0.90
|
|
69
|
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.
|
J Clin Oncol
|
2009
|
0.90
|
|
70
|
Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab.
|
Stem Cells Transl Med
|
2012
|
0.89
|
|
71
|
Concordance of cancer patients' function, symptoms, and supportive care needs.
|
Qual Life Res
|
2009
|
0.89
|
|
72
|
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer.
|
Clin Cancer Res
|
2004
|
0.89
|
|
73
|
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.
|
Clin Cancer Res
|
2003
|
0.88
|
|
74
|
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.87
|
|
75
|
Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.86
|
|
76
|
Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer.
|
Cancer Biol Ther
|
2011
|
0.86
|
|
77
|
Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers.
|
Drug Saf
|
2002
|
0.86
|
|
78
|
Breast cancer.
|
J Natl Compr Canc Netw
|
2005
|
0.85
|
|
79
|
Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria.
|
J Natl Cancer Inst
|
2012
|
0.84
|
|
80
|
Feasibility trial of partial breast irradiation with concurrent dose-dense doxorubicin and cyclophosphamide in early-stage breast cancer.
|
J Clin Oncol
|
2009
|
0.84
|
|
81
|
It's who you know: patient-sharing, quality, and costs of cancer survivorship care.
|
J Cancer Surviv
|
2014
|
0.83
|
|
82
|
With maturity comes confidence: EBCTCG tamoxifen update.
|
Lancet
|
2011
|
0.81
|
|
83
|
In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent.
|
Clin Cancer Res
|
2005
|
0.81
|
|
84
|
Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
|
Clin Breast Cancer
|
2007
|
0.81
|
|
85
|
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
|
Breast Cancer Res Treat
|
2013
|
0.81
|
|
86
|
Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer.
|
Clin Breast Cancer
|
2010
|
0.80
|
|
87
|
Complete radiologic response and long-term survival with use of systemic high-dose methotrexate for breast cancer-associated leptomeningeal disease.
|
Clin Breast Cancer
|
2012
|
0.80
|
|
88
|
Estrogen receptor: a never ending story?
|
J Clin Oncol
|
2011
|
0.79
|
|
89
|
The role of ovarian ablation in the adjuvant therapy of breast cancer.
|
Curr Oncol Rep
|
2008
|
0.79
|
|
90
|
Adjuvant chemotherapy for postmenopausal lymph node-negative breast cancer: it ain't necessarily so.
|
J Natl Cancer Inst
|
2002
|
0.78
|
|
91
|
Evaluating information prescriptions in two clinical environments.
|
J Med Libr Assoc
|
2011
|
0.78
|
|
92
|
Breast cancer: noninvasive and special situations.
|
J Natl Compr Canc Netw
|
2010
|
0.78
|
|
93
|
A rapid and sensitive method for determination of dimethyl benzoylphenyl urea in human plasma by using LC/MS/MS.
|
J Pharm Biomed Anal
|
2003
|
0.78
|
|
94
|
A method for determination of dimethyl benzoylphenyl urea (BPU) in human plasma by using LC/UV.
|
Biomed Chromatogr
|
2004
|
0.78
|
|
95
|
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).
|
Breast Cancer Res Treat
|
2015
|
0.78
|
|
96
|
Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.
|
Expert Rev Anticancer Ther
|
2007
|
0.78
|
|
97
|
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
|
Breast Cancer Res Treat
|
2014
|
0.78
|
|
98
|
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate dimethyl benzoylphenylurea (BPU) and its five metabolites in human plasma and urine for clinical pharmacology studies.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2005
|
0.78
|
|
99
|
Detection of circulating tumor cells in the cerebrospinal fluid: a new frontier.
|
Cell Cycle
|
2012
|
0.77
|
|
100
|
Perceptions and needs of women with metastatic breast cancer: a focus on clinical trials.
|
Breast
|
2013
|
0.77
|
|
101
|
Reply to G. Sauter et al.
|
J Clin Oncol
|
2009
|
0.77
|
|
102
|
Coordination of care in breast cancer survivors: an overview.
|
J Support Oncol
|
2011
|
0.76
|
|
103
|
Still waiting after 110 years: the optimal use of ovarian ablation as adjuvant therapy for breast cancer.
|
J Clin Oncol
|
2006
|
0.76
|
|
104
|
The androgen receptor in breast cancer: learning from the past.
|
Breast Cancer Res Treat
|
2010
|
0.76
|
|
105
|
Pregnancy and fertility with breast cancer: what are the options?
|
Oncology (Williston Park)
|
2009
|
0.75
|
|
106
|
International disparity in breast cancer outcomes: the time to close the gap is now.
|
Oncology (Williston Park)
|
2010
|
0.75
|
|
107
|
Anastrozole is safer and may be more effective than tamoxifen in postmenopausal women with early-stage breast cancer.
|
Cancer Treat Rev
|
2004
|
0.75
|
|
108
|
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
|
Eur J Cancer
|
2006
|
0.75
|
|
109
|
Comparison of breast cancer risk in women with and without systemic lupus erythematosus in a Medicare population.
|
Breast Cancer Res Treat
|
2015
|
0.75
|
|
110
|
Omics as useful tools in clinical practice: are we there yet?
|
Oncology (Williston Park)
|
2013
|
0.75
|
|
111
|
Local failure and prognostic factors in ductal carcinoma in situ: concentration on recent publications.
|
Curr Opin Obstet Gynecol
|
2003
|
0.75
|